Phase 1 Safety and Pharmacokinetic Study of AI-700 in Patients With Diminished DLCO and COPD and/or CHF
Phase 1 Safety and Pharmacokinetic Study of AI-700 in Patients With Diminished DLCO and COPD and/or CHF
This study was conducted to evaluate the safety and pharmacokinetics of an echocardiographic
 contrast agent, AI-700, in patients with moderate to severe chronic obstructive pulmonary
 disease (COPD) and/or congestive heart failure (CHF).
In ongoing clinical trials, AI-700 is currently being evaluated for its value to provide
 enhanced echocardiography to detect CAD. The patient population is comprised of those
 patients who have chest pain and are being evaluated for inducible ischemia. This population
 may include patients with compromised pulmonary function due to COPD or CHF. This study was
 to evaluate the safety of AI-700 in these patients.